Ora, Inc. Partners with the North West London Clinical Trials Alliance to Accelerate Patient Access to Cutting-Edge Ophthalmology Treatments
Ora, Inc., the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today its partnership with the North West London Clinical Trials Alliance (NWL Clinical Trials Alliance), a collaboration between clinical trial teams that aims to improve access to and the quality of clinical research in the region.
This strategic partnership comes at a pivotal time as the UK government emphasizes the importance of innovative partnerships and encourages increased, multi-sector collaboration. The partnership between Ora and the NWL Clinical Trials Alliance directly supports this initiative bringing together academia, industry and the NHS to provide better solutions that will address the gap in patient-access to cutting-edge treatment options.
“Ora and the NWL Clinical Trials Alliance share a common goal: improve access to, and the quality of, clinical research in Europe,” said Stuart Abelson, CEO Ora. “Ora’s well-established leadership position in ophthalmology research, coupled with the reach and relationships established by the NWL Clinical Trials Alliance, will provide our sponsors with an increased level of confidence to deliver European-based early and late-phase research studies.”
For sponsors planning or considering trial delivery in Europe, Ora and the NWL Clinical Trials Alliance will provide:
- Comprehensive analysis of country and site selection, that includes candid feedback based on open and honest communication with study sites.
- Access to a diverse group of study participants eager to receive new treatment options.
- Operational excellence delivered by a seasoned team of ophthalmology-focused resources committed to delivering trials with speed, efficiency, quality, and cost-savings.
“We are honoured to partner with a globally recognized leader in ophthalmology research,” said Dr Suki Balendra, director of NWL Clinical Trials Alliance. “Collaborating with Ora not only improves outcomes for historically underrepresented patient populations but provides an opportunity to explore new and innovative ways to increase clinical trial access for all patients. Europe is in a position to accelerate getting drugs to market faster, while simultaneously helping to build a robust and sustainable clinical research ecosystem beyond the US", she continued.
About Ora, Inc.
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 82 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn
Ora® and Ora Logo are registered trademarks of Ora, Inc.
About North West London Clinical Trials Alliance
The North West London Clinical Trials Alliance is dedicated to delivering commercial and non-commercial sponsored clinical trials – utilising existing and purpose-designed facilities to successfully deliver both early and late-phase research. It aims to increase regional capacity for delivering commercial clinical research, as well as to improve the ease and speed of research delivery, patient access to clinical research and patient opportunities for early access to cutting edge treatment and therapies that are not yet widely available through the NHS. This will be achieved through collaborative working, using our understanding of the needs and priorities of life science companies and our strong regional team ethos to work in a harmonised manner across centres. The ophthalmology unit at London North West University Healthcare NHS Trust, which is part of the North West London Clinical Trials Alliance, is recognised nationally as one of the leaders in delivery of commercial trials and is committed to widening access to novel and innovative treatments for the UK’s diverse communities to improve on health outcomes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712806839/en/
Contact information
Media
Claire Russell
crussell@oraclinical.com
+1 (919) 597-9029
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pogust Goodhead and Gramercy Funds Management LLC Announce $552.5 Million Investment Partnership1.10.2023 16:13:00 EEST | Press release
Pogust Goodhead, a global law firm, and Gramercy Funds Management LLC (“Gramercy”), today announced that they have entered into a $552.5 million investment partnership in the form of a secured loan by Gramercy to Pogust Goodhead. This loan is the largest of its kind in a U.K. based law firm. The loan transaction strengthens the firm’s financial power, ensuring Pogust Goodhead has ample funds to continue its litigation across the world and on behalf of environmental victims of corporate giants such as: BHP Group (BHP.AX), BMW (BMWG.DE), Fiat Chrysler (STLAM.MI), Ford (F), Honda (7267.T), Hyundai (005380.KS), Jaguar/Land Rover (JLR), Mazda (7261.T), Mercedes-Benz (MBGn.DE), Peugeot/Citroen (PEUG.PA), Renault Nissan (RENA.PA), Toyota (7203.T), Vauxhall (STLAM.MI), Volkswagen AG (VOWG.DE), and Volvo AB (VOLVb.ST). The loan proceeds will fund the largest action of its kind against two of the biggest mining companies in the world – BHP Group (BHP.AX) and Vale (VALE3.SA) – for their part in t
PUMA Called Ambassadors From All Around the World to Form “Class of 23”1.10.2023 13:00:00 EEST | Press release
Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231001418878/en/ Global sports company PUMA launches a beanies campaign, “Class of 23”, to unite ambassadors from across the globe to represent of the close-knit PUMA family. (Photo: Business Wire) 2023 means a long journey for PUMA, which was made with the remarkable people behind it. “Class of 23” is the right way to celebrate the inspiring ambassadors and talents PUMA has collaborated with over the past 75 years. Each talent, from Neymar Jr. and Pamela Reif to Gianmarco Tamberi and Winnie Harlow, was captured in a personalized way, wearing their favorite PUMA beanies from the 2023 collection to show their membership in the grand PUMA family. “Our PUMA family is the heartbeat of our brand, co-created with the brilliance
Optomind and MaxLinear announce collaboration on PAM4 112Gbps OSFP 800Gbps SR8 transceiver solution at ECOC Exhibition 20231.10.2023 09:00:00 EEST | Press release
Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear). Optomind has developed the best-in-class PAM4 100Gbps/lane SR optical transceivers and AOCs using MaxLinear's 5nm Keystone PAM4 DSP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230930086952/en/ Advancing data transmission rates to 100Gbps per lane drastically transforms the ecosystem of data centers, especially AI/ML and HPC. Training AI and GPT workloads drive huge and high-density networks utilizing large numbers of servers connected together through rack switches over short reach links. The low-power, high-performance AOCs and transceivers that Optomind and MaxLinear have developed together are ideal for these applications. Optomind selected MaxLinear's 5nm Keystone PAM4 DSP as the best-in-class solution for
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom